Renovacor (NYSE:RCOR – Get Rating) is one of 270 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare Renovacor to similar companies based on the strength of its dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.
This table compares Renovacor and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and target prices for Renovacor and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings & Valuation
This table compares Renovacor and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Renovacor Competitors||$754.48 million||$143.11 million||4.33|
Renovacor’s competitors have higher revenue and earnings than Renovacor. Renovacor is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Renovacor has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. Comparatively, Renovacor’s competitors have a beta of 0.69, suggesting that their average share price is 31% less volatile than the S&P 500.
Institutional & Insider Ownership
45.8% of Renovacor shares are owned by institutional investors. Comparatively, 47.3% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 14.4% of Renovacor shares are owned by insiders. Comparatively, 16.8% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Renovacor competitors beat Renovacor on 8 of the 13 factors compared.
Renovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.
Receive News & Ratings for Renovacor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renovacor and related companies with MarketBeat.com's FREE daily email newsletter.